Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study.

Van Damme P, De Coster I, Bandyopadhyay AS, Revets H, Withanage K, De Smedt P, Suykens L, Oberste MS, Weldon WC, Costa-Clemens SA, Clemens R, Modlin J, Weiner AJ, Macadam AJ, Andino R, Kew OM, Konopka-Anstadt JL, Burns CC, Konz J, Wahid R, Gast C.

Lancet. 2019 Jul 13;394(10193):148-158. doi: 10.1016/S0140-6736(19)31279-6. Epub 2019 Jun 4.

2.

Continued use of poliovirus after eradication: hyper-attenuated strains as a safe alternative for release testing of human immunoglobulins.

Farcet MR, Modrof J, Rabel PO, Schirmer A, Macadam AJ, Fox H, Minor PD, Kreil TR.

Transfusion. 2018 Dec;58 Suppl 3:3084-3089. doi: 10.1111/trf.15048.

PMID:
30536436
3.

Plant-made polio type 3 stabilized VLPs-a candidate synthetic polio vaccine.

Marsian J, Fox H, Bahar MW, Kotecha A, Fry EE, Stuart DI, Macadam AJ, Rowlands DJ, Lomonossoff GP.

Nat Commun. 2017 Aug 15;8(1):245. doi: 10.1038/s41467-017-00090-w.

4.

Pathogenic Events in a Nonhuman Primate Model of Oral Poliovirus Infection Leading to Paralytic Poliomyelitis.

Shen L, Chen CY, Huang D, Wang R, Zhang M, Qian L, Zhu Y, Zhang AZ, Yang E, Qaqish A, Chumakov K, Kouiavskaia D, Vignuzzi M, Nathanson N, Macadam AJ, Andino R, Kew O, Xu J, Chen ZW.

J Virol. 2017 Jun 26;91(14). pii: e02310-16. doi: 10.1128/JVI.02310-16. Print 2017 Jul 15.

5.

Genetically Thermo-Stabilised, Immunogenic Poliovirus Empty Capsids; a Strategy for Non-replicating Vaccines.

Fox H, Knowlson S, Minor PD, Macadam AJ.

PLoS Pathog. 2017 Jan 19;13(1):e1006117. doi: 10.1371/journal.ppat.1006117. eCollection 2017 Jan.

6.

New Strains Intended for the Production of Inactivated Polio Vaccine at Low-Containment After Eradication.

Knowlson S, Burlison J, Giles E, Fox H, Macadam AJ, Minor PD.

PLoS Pathog. 2015 Dec 31;11(12):e1005316. doi: 10.1371/journal.ppat.1005316. eCollection 2015 Dec.

7.

Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication.

Macadam AJ, Ferguson G, Stone DM, Meredith J, Knowlson S, Auda G, Almond JW, Minor PD.

J Virol. 2006 Sep;80(17):8653-63.

8.

Live-attenuated strains of improved genetic stability.

Macadam AJ, Ferguson G, Stone DM, Meredith J, Almond JW, Minor PD.

Dev Biol (Basel). 2001;105:179-87. Review.

PMID:
11763326
9.

Functional formation of domain V of the poliovirus noncoding region: significance of unpaired bases.

Rowe A, Burlison J, Macadam AJ, Minor PD.

Virology. 2001 Oct 10;289(1):45-53.

10.

Coding changes in the poliovirus protease 2A compensate for 5'NCR domain V disruptions in a cell-specific manner.

Rowe A, Ferguson GL, Minor PD, Macadam AJ.

Virology. 2000 Apr 10;269(2):284-93.

11.

Laboratory tests for live attenuated poliovirus vaccines.

Wood DJ, Macadam AJ.

Biologicals. 1997 Mar;25(1):3-15. Review.

PMID:
9167004
12.

Role of mutations G-480 and C-6203 in the attenuation phenotype of Sabin type 1 poliovirus.

McGoldrick A, Macadam AJ, Dunn G, Rowe A, Burlison J, Minor PD, Meredith J, Evans DJ, Almond JW.

J Virol. 1995 Dec;69(12):7601-5.

14.

The 5' noncoding region and virulence of poliovirus vaccine strains.

Macadam AJ, Stone DM, Almond JW, Minor PD.

Trends Microbiol. 1994 Nov;2(11):449-54. Review.

PMID:
7866703
15.

Role for poliovirus protease 2A in cap independent translation.

Macadam AJ, Ferguson G, Fleming T, Stone DM, Almond JW, Minor PD.

EMBO J. 1994 Feb 15;13(4):924-7.

16.

Genetic basis of attenuation of the Sabin oral poliovirus vaccines.

Minor PD, Macadam AJ, Stone DM, Almond JW.

Biologicals. 1993 Dec;21(4):357-63. Review. No abstract available.

PMID:
8024751
17.

Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates.

Macadam AJ, Pollard SR, Ferguson G, Skuce R, Wood D, Almond JW, Minor PD.

Virology. 1993 Jan;192(1):18-26.

PMID:
8390752
18.

Approaches to the construction of new candidate poliovirus type 3 vaccine strains.

Almond JW, Stone D, Burke K, Skinner MA, Macadam AJ, Wood D, Ferguson M, Minor PD.

Dev Biol Stand. 1993;78:161-9; discussion 169-70. Review.

PMID:
8388827
19.

Correlation of RNA secondary structure and attenuation of Sabin vaccine strains of poliovirus in tissue culture.

Macadam AJ, Ferguson G, Burlison J, Stone D, Skuce R, Almond JW, Minor PD.

Virology. 1992 Aug;189(2):415-22.

PMID:
1641974
20.
21.

The 5' noncoding region of the type 2 poliovirus vaccine strain contains determinants of attenuation and temperature sensitivity.

Macadam AJ, Pollard SR, Ferguson G, Dunn G, Skuce R, Almond JW, Minor PD.

Virology. 1991 Apr;181(2):451-8.

PMID:
1707566
22.

Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccinees.

Macadam AJ, Arnold C, Howlett J, John A, Marsden S, Taffs F, Reeve P, Hamada N, Wareham K, Almond J, et al.

Virology. 1989 Oct;172(2):408-14.

PMID:
2552655
23.

Structural factors that control conformational transitions and serotype specificity in type 3 poliovirus.

Filman DJ, Syed R, Chow M, Macadam AJ, Minor PD, Hogle JM.

EMBO J. 1989 May;8(5):1567-79.

Supplemental Content

Loading ...
Support Center